A Study of JZP815 Oral Capsules
Phase 1
332
about 5.5 years
18+
14 sites in CO, FL, IL +6
About this study
This trial is testing a treatment called JZP815 in adults with advanced or metastatic solid tumors that have changes in the MAPK pathway. The goal is to learn about its safety, how it works in the body (pharmacokinetics), and if it can kill cancer cells (antitumor activity).
Based on ClinicalTrials.gov records.
What participants do
- 1.Take JZP815
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change From Baseline in Absolute Neutrophil Count (Part A and B), Change From Baseline in Alanine Aminotransferase (Part A and B), Change From Baseline in Aspartate Aminotransferase (Part A and B), Change From Baseline in Blood Pressure (Part A and B), Change From Baseline in Creatinine (Part A and B), Change From Baseline in Heart Rate (Part A and B), Change From Baseline in Hematocrit (Part A and B), Change From Baseline in Hemoglobin (Part A and B)
Secondary: Objective Response Rate (as Defined by RECIST v1.1) (Part A), Overall Survival (Part B), Pharmacokinetic Parameter Accumulation Ratio of JZP815 and its Metabolites (Part A), Pharmacokinetic Parameter Apparent Terminal Elimination Half-life (t1/2) of JZP815 and its Metabolites (Part A), Pharmacokinetic Parameter Apparent Volume of Distribution During Terminal Phase (Vz/F) of JZP815 (Part A), Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP815 and its Metabolites (Part A), Pharmacokinetic Parameter Clearance (CL/F) of JZP815 (Part A), Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP815 and its Metabolites (Part A)
Oncology